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A series of colistin-resistant Klebsiella pneumoniae isolates recovered from different countries was investigated in order to eval-
uate the involvement of the PmrA/PmrB two-component system in this resistance. Six isolates possessed a mutated PmrB pro-
tein, which is encoded by the pmrB gene, part of the pmrCAB operon involved in lipopolysaccharide modiﬁcation. The same
amino acid substitution (Thr157Pro) in PmrB was identiﬁed in the six isolates. The six isolates belonged to four distinct clonal
groups, recovered in South Africa (sequence type 14 [ST14]), Turkey (ST101), and Colombia (ST258 and ST15). Three out of the
four clones produced a carbapenemase, OXA-181, OXA-48, or KPC-3, while a single isolate did not produce any carbapenemase.
Expression assays revealed an overexpression of the pmrA (70-fold), pmrB (70-fold), pmrC (170-fold), and pmrK (40-fold) genes
in the pmrB-mutated isolate compared to expression of the pmrB wild-type isogenic K. pneumoniae isolate, conﬁrming that the
PmrB substitution was responsible for increased expression levels of those genes. Complementation assays leading to the expres-
sion of a wild-type PmrB protein restored the susceptibility to colistin in all isolates, conﬁrming that the substitution in PmrB
was responsible for the resistance phenotype. This study identiﬁed a key amino acid located in the PmrB protein as being re-
sponsible for the overexpression of pmrCAB and pmrHFIJKLM operons, leading to resistance to colistin.
Klebsiella pneumoniae is a Gram-negative pathogen often asso-ciatedwith nosocomial infections, including pneumonia, bac-
teremia, urinary tract infection, and sometimes even life-threat-
ening septic shock (1). Infection caused by multidrug-resistant
(MDR) K. pneumoniae is now a worldwide issue, considering the
wide dissemination of MDR clones. In particular, the recent
worldwide emergence of carbapenemase-producing isolates has
often resulted in very limited therapeutic options. As a conse-
quence, polymyxin antibiotics are now considered the last resort
in the armamentarium for treatment of infections caused byMDR
Gram-negative pathogens.
Polymyxins are derivatives of the Bacillus polymyxa subspecies
colistinus that are active only against Gram-negative bacteria.
Structurally, they are decapeptides bound to a fatty acid chain (2).
The clinically available forms, polymyxin B and colistin (also
known as polymyxin E), are administered intravenously or by
inhalation. Like other antimicrobial peptides (APs), colistin inter-
acts with the lipid A moiety of the Gram-negative bacterial lipo-
polysaccharide (LPS). The polycationic peptide ring competes for
and substitutes the calcium andmagnesiumbridges stabilizing the
LPS, promoting membrane permeability and thus disrupting the
integrity of the outer membrane of Gram-negative bacteria, thus
leading to bacterial death (2).
Nevertheless, resistance to polymyxins has been reported in K.
pneumoniae, but little is known about the molecular mechanisms
sustaining this resistance trait. The two-component regulatory
systems (TCS) PmrA/PmrB and PhoP/PhoQ have been identiﬁed
as regulatory systems involved in the resistance to polymyxin B
(3). The insertional inactivation of the PhoQ/PhoP mgrB-encod-
ing regulator has also been recently associated with colistin resis-
tance (4, 5).
The main mechanisms leading to resistance to polymyxins are
modiﬁcations of the bacterial outer membrane, mainly through
the covalent addition of both phosphoethanolamine (pEtN) and
4-deoxyaminoarabinose (Lara4N) to the LPS (6–8). The pmrCAB
operon encodes the PmrC phosphoethanolamine phosphotrans-
ferase, the PmrA response regulator (also named BasR), and the
PmrB sensor kinase (also named BasS) (6). In Escherichia coli and
Salmonella enterica species, PmrB acts as a sensor cytoplasmic
membrane-bound kinase activated by high concentrations of iron
(Fe3) and an acidic pH (pH 5.5). Upon activation, it activates
PmrA by phosphorylation (2). In vivo, PmrAB is involved in sens-
ing the environment and is required for intramacrophage survival
and virulence (6). Mutations in the pmrA or pmrB genes usually
result in constitutive activation of PmrA, which upregulates in
turn three loci, namely, pmrC encoding an aminotransferase in-
volved in the decoration of the LPS with pEtN, pmrE (previously
identiﬁed as pagA or ugd) encoding a UDP-glucose dehydroge-
nase, which is the ﬁrst enzyme in the Ara4N biosynthetic pathway,
and the pmrHFIJKLM operon (also called pmrF, pbg, or arn
operon) encoding enzymes responsible for the synthesis and
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transfer of the Lara4N to lipid A (6). Overall, this constitutive
activation of PmrA leads to a more positively charged LPS, thus
reducing the afﬁnity of positively charged polymyxins.
Using a collection of K. pneumoniae isolates recovered world-
wide, in this studywe aimed to investigatewhether themechanism
leading to resistance to colistin might be related to the PmrAB
two-component system.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Thirty-ﬁve colistin-resistant K.
pneumoniae clinical isolates were included in this study. They had been
collected in France, Turkey, Colombia, and South Africa. Isolates were
identiﬁed by using the API20E system (bioMérieux, Marcy l’Etoile,
France). E. coli TOP10 (Invitrogen, Illkirch, France) was used as the host
strain for cloning experiments with selection based on kanamycin (50
g/ml). Colistin-resistant K. pneumoniae clinical isolates were also used
for transformation assays and selection based on zeocin (a formulation of
phleomycin D1, a glycopeptide antibiotic produced by Streptomyces ver-
ticillus) (100 g/ml).
Antimicrobial susceptibility assays.The antibiotic susceptibility test-
ing was performed using Etest strips (AB bioMérieux, La Balme-les-
Grottes, France) on Mueller-Hinton agar plates (Bio-Rad, Marnes-la-Co-
quette, France) with 0.5 McFarland standard inoculum. MICs were also
determined by broth microdilution in cation-adjusted Mueller-Hinton
broth (MHB-CA) according to CLSI guidelines (9–11). Polymyxin B and
colistin (Sigma-Aldrich, Saint-Quentin Fallavier, France)were testedwith
Tween 80 (a surfactant preventing binding of colistin to drug panels) over
a range of dilution from 0.125 to 64g/ml (9, 12). Brieﬂy, MHB-CA with
a ﬁnal concentration of 0.002% Tween 80 and 5  105 CFU/ml in each
well was used. Following the EUCAST breakpoints (http://www.eucast
.org/), isolates with a colistin MIC of2 g/ml were categorized as sus-
ceptible, although those with MICs of2 g/ml were resistant.
PCR ampliﬁcation and sequencing.The chromosomal DNA was iso-
lated using the commercially available QIAquick kit (Qiagen, Courta-
boeuf, France), according to the manufacturer’s instructions. The pmrA,
pmrB, phoP, phoQ, and mgrB genes possibly involved in resistance to
colistin were ampliﬁed using speciﬁc oligonucleotides (Table 1). The PCR
ampliﬁcation for detection of the narrow- and expanded-spectrum-lac-
tamase genes blaCTX-M, blaSHV, blaTEM, blaOXA, blaOXA-48-like, and blaKPC
was carried out as described previously (13, 14). The ampliﬁed DNA frag-
ments were puriﬁed with the QIAquick PCR puriﬁcation kit (Qiagen).
Both strands of the ampliﬁcation products obtained were sequenced with
an ABI 3100 sequencer (Applied Biosystems, Foster City, CA). The nucle-
otide and deduced protein sequences were analyzed at the National Cen-
ter for Biotechnology Information website (www.ncbi.nlm.nih.gov) by
the Basic Local Alignment Search Tool (BLAST) program.
Analysis of the primary and secondary structures of the PmrB pro-
tein. The primary structure of the PmrB protein was analyzed using the
Ensembl Bacteria database (http://bacteria.ensembl.org/index.html). The
predicted secondary structures of the two PmrB proteins (wild-type and
mutated) were obtained using the GOR method with EMBOSS 6.3.1 soft-
ware, available on the Mobyle@Pasteur portal (http://mobyle.pasteur.fr
/cgi-bin/portal.py).
Complementation assays. The pmrB gene from the K. pneumoniae
reference strain ATCC 53153 (colistinMIC of 0.125g/ml) was ampliﬁed
by PCR using 2 Phusion HF master mix (Finnzymes; Life Technologies,
Illkirch, France) and primers pmrB ext F and pmrB ext R. The partial and
therefore noncoding mdh sequence (supposed to encode a malate dehy-
drogenase [15]) was PCR ampliﬁed with primers mdh ext F and mdh ext
R (Table 1).Using theZeroBlunt TOPOPCRcloning kit (Invitrogen), the
ampliﬁed fragments were cloned into the high-copy-number plasmid
pCR-BluntII-TOPO encoding resistance to kanamycin and zeocin. The
resulting plasmids pTOPO-pmrB andpTOPO-mdhwere separately trans-
formed into electrocompetent E. coli TOP10 strains by electroporation.
Transformants were selected by overnight incubation at 37°C onMueller-
Hinton agar supplemented with kanamycin (50 g/ml). Plasmids were
then isolated using the QIAprep spin miniprep column kit (Qiagen) and
transformed into colistin-resistant K. pneumoniae clinical isolates. Trans-
formants were selected by overnight incubation at 37°C on Mueller-Hin-
ton agar supplemented with zeocin (100 g/ml), and the presence of the
cloned gene was checked by PCR. The MICs of transformants for colistin
and polymyxin were determined as described above.
Strain genotyping by PFGE andMLST.The genetic relatedness of the
isolates was assessed by pulsed-ﬁeld gel electrophoresis (PFGE) analysis
with XbaI-digested genomic DNA as described previously (16). Multilo-
cus sequence typing (MLST) was carried out with seven standard house-
keeping loci (rpoB, gapA, mdh, pgi, phoE, infB, and tonB) according to
Diancourt et al. (15). Sequence types were analyzed by using the Institut
Pasteur database (http://www.pasteur.fr/recherche/genopole/PF8/mlst
/Kpneumoniae.html).
Growth curves. In order to evaluate the putative impact of modiﬁed
LPS, growth curves were determined. Brieﬂy, 200 ml Luria broth was
inoculated independently with 108 CFU of each strain, and cultures were
grown for 24 h at 37°C under gentle shaking. Absorbance at a wavelength
of 600 nmwasmeasured during 24 h. The colony countingwas performed
by serial dilution and ﬁnal plating on solid medium. Experiments were
repeated three times. Zeocin (100 g/ml) was added to the growth me-
dium in order to select the recombinant plasmids when K. pneumoniae
strainAF1b complementedwith pTOPO-pmrBor pTOPO-mdhwas used.
Transcriptional analysis by quantitative real-time PCR. Quantita-
tive real-time PCR (qRT-PCR) was used to measure the expression of the
pmrC, pmrA, pmrB, pmrD, pmrE, and pmrK genes, using the primers listed
in Table 1. RNA preparations were obtained using the RNeasy minikit
(Qiagen), according to the manufacturer’s instructions. qRT-PCR was
carried out using a Rotor-Gene Q instrument (Qiagen). Expression of the
rpsL gene encoding a ribosomal protein was evaluated with the primers
rpsL int F and rpsL int R (Table 1), and this expression rate was used as a
signal reporter (4). QuantiFast SYBR green (Qiagen) was used as an in-
TABLE 1 Oligonucleotides used in this study
Primer Sequence (5= to 3=) Gene
Reference
or source
pmrA ext F CAT TTC CGC GCA CTG TCT GC pmrA This study
pmrA ext R CAG CTT TCA GTT GCA AAC AG pmrA This study
pmrB ext F ACC TAC GCG AAA AGA TTG GC pmrB This study
pmrB ext R GAT GAG GAT AGC GCC CAT GC pmrB This study
phoP ext F GAG CTT CAG ACT ACT ATC GA phoP This study
phoP ext R GGG AAG ATA TGC CGC AAC AG phoP This study
phoQ ext F ATA CCC ACA GGA CGT CAT CA phoQ This study
phoQ ext R CAG GTG TCT GAC AGG GAT TA phoQ This study
mgrB ext F TTA AGA AGG CCG TGC TAT CC mgrB 4
mgrB ext R AAG GCG TTC ATT CTA CCA CC mgrB 4
mdh ext F CCC AAC TCG CTT CAG GTT CAG mdh 15
mdh ext R CCG TTT TTC CCC AGC AGC AG mdh 15
pmrC int F GCG TGA TGA ATA TCC TCA CCA pmrC This study
pmrC int R CAC GCC AAA GTT CCA GAT GA pmrC This study
pmrA int F GAT GAA GAC GGG CTG CAT TT pmrA This study
pmrA int R ACC GCT AAT GCG ATC CTC AA pmrA This study
pmrB int F TGC CAG CTG ATA AGC GTC TT pmrB This study
pmrB int R TTC TGG TTG TTG TGC CCT TC pmrB This study
pmrD int F GAT CGC AGA GAT TGA AGC CT pmrD This study
pmrD int R GCG TTG CGG ATC TTC AAA GT pmrD This study
pmrE int F GCA TAC CGT AAT GCC GAC TA pmrE This study
pmrE int R GGG TTG ATC TCT GTG ACA TC pmrE This study
pmrK int F AGT ATC GGT CAG TGG CTG TT pmrK This study
pmrK int R CCG CTT ATC ACG AAA GAT CC pmrK This study
rpsL int F CCG TGG CGG TCG TGT TAA AGA rpsL 4
rpsL int R GCC GTA CTT GGA GCG AGC CTG rpsL 4
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ternal standard (4). Data were compared to those obtained with the rpsL
gene using the threshold cycle (CT) method (relative), and the ob-
tained values were then normalized against the values obtained for the
susceptible isolate. Experiments were repeated three times.
Nucleotide sequence accession number. The nucleotide and protein
sequences of the mutated PmrB protein were registered in GenBank un-
der accession no. KJ626267.
RESULTS
Apointmutation in thepmrB gene of colistin-resistantK. pneu-
moniae isolates. Sequence analysis of the pmrB genes of all the
colistin-resistant clinical isolates from our collection revealed the
same single-nucleotide substitution (A to C) in six isolates (AF1b,
C3, C4, C19, T2, and T3) compared to those in the pmrB gene
sequences from K. pneumoniae available in GenBank (Table 2).
No amino acid substitutions were identiﬁed in the PmrA, PhoP,
PhoQ, and MgrB proteins in those isolates compared with se-
quences obtained from wild-type isolates (data not shown). This
mutated PmrB protein differed from the wild type by a single
threonine to proline amino acid substitution at position 157.
Since a colistin-susceptible isolate, AF1a (colistin MIC of 0.125
g/ml), recovered from the same patient from whom the colistin-
resistant isolate AF1b had been recovered was available (17), its
pmrB gene was also sequenced. A Thr residue was identiﬁed at
position 157 (as for the other wild-type strains), thus reinforcing
the hypothesis that Thr157Pro might play a key role in acquired
resistance to colistin (Table 2).
Impact of amino acid 157 substitutionon the structure of the
PmrB protein. By analyzing the primary structure of the PmrB
protein, amino acid 157was identiﬁed in the PmrBdomain,which
is involved in the dimerization of the protein. We might speculate
that the replacement of a polar by a nonpolar amino acid in this
domain may have a signiﬁcant impact in the dimerization process
of PmrB and therefore induce constitutive activation of PmrA.
The predicted secondary structures of the two PmrB proteins
(wild type and mutated) revealed that the Thr157Pro amino acid
substitution signiﬁcantly modiﬁed the secondary structure of the
mutated protein, with an interruption of the alpha-helix (see Fig.
S1 in the supplemental material).
Thr157Pro substitution in protein PmrB identiﬁed among
clonally unrelated colistin-resistant K. pneumoniae isolates.
The genetic relationship of the six colistin-resistant isolates exhib-
iting the same Thr157Pro substitution, together with the colistin-
susceptible isolate AF1a, was evaluated. PFGE analysis conﬁrmed
that isolates AF1a and AF1b recovered from a single patient were
clonally related (17) (data not shown). In addition, isolates C3 and
C4, recovered from two patients from the same hospital, were also
clonally related, and isolates T2 and T3, again from two patients
from the same hospital, were clonally related (data not shown).
Overall, four colistin-resistant clones were identiﬁed (Table 2).
Further data obtained byMLSTwere in accordancewith the PFGE
results (Table 2).
Identiﬁcationof additional resistancemechanisms tobroad-
spectrum -lactams. The clonally related isolates AF1a (colistin-
susceptible) and AF1b (colistin-resistant) recovered from South
Africa were found to produce the OXA-181 (OXA-48-like) car-
bapenemase (Table 2). The clonally related C3 and C4 isolates
from Colombia produced carbapenemase KPC-3. Isolate C19
from Colombia, clonally unrelated compared to other isolates in
this study, did not produce any carbapenemase. Finally, clonally
related isolates T2 and T3 recovered from Turkey produced car-
bapenemase OXA-48.
Complementation experiments. To determine whether resis-
tance to colistin might be related to the PmrB mutation, comple-
mentation experiments were performed for each clonally unre-
lated strain (AF1b, C3, C19, and T2). The wild-type pmrB gene
was cloned into the high-copy-number plasmid pCR-BluntII-
TOPO, which was then transformed into the colistin-resistant
clinical isolates. The results of complementation showed a com-
plete reversion to susceptibility to colistin when we transformed
each of those resistant isolates with plasmid pTOPO-pmrB (Table
3). As expected, transformation with plasmid pTOPO-mdh used
as a negative control did not restore the susceptibility to colistin.
Additionally, three other clonally unrelated and colistin-resis-
tant K. pneumoniae for which no substitution was identiﬁed in
PmrB were transformed with plasmid pTOPO-pmrB encoding
the wild-type PmrB. MICs of colistin remained unchanged, thus
showing that restoration of the susceptibility to colistin by com-
plementation with a wild-type PmrB protein was not due to PmrB
overproduction. This was also a direct proof of the involvement of
the protein PmrB in the resistance pattern to colistin.
Growth rates of colistin-susceptible and colistin-resistant
strains. No difference was observed between the growth of isogenic
K. pneumoniae AF1a (colistin-susceptible) and AF1b (colistin-re-
sistant) isolates, thus suggesting that the PmrB substitution and
TABLE 2 MICs, molecular features, and genotyping analysis of K. pneumoniae isolates carrying the pmrB gene mutation and of isolate AF1a, the
isogenic colistin-susceptible counterpart of AF1b
Isolate
Country of
isolation
MIC (g/ml) fora:
Colistin
proﬁleb
PmrB amino
acid change Carbapenemase ESBLc
Additional
-lactamases MLSTd
PFGEe
pulsotypeERT IPM MEM DOR CST
AF1a South Africa 32 32 32 32 0.125 S WTf OXA-181 CTX-M-15 TEM-1, SHV-1 ST14 1
AF1b South Africa 32 32 32 32 3 R T157P OXA-181 CTX-M-15 TEM-1, SHV-1 ST14 1
C3 Colombia 32 32 32 32 4 R T157P KPC-3 None TEM-1, SHV-1 ST258 2
C4 Colombia 32 32 32 32 4 R T157P KPC-3 None TEM-1, SHV-1 ST258 2
C19 Colombia 0.25 0.19 0.094 0.064 4 R T157P None None TEM-1, SHV-1 ST15 3
T2 Turkey 16 32 32 24 6 R T157P OXA-48 CTX-M-15 TEM-1, SHV-1, OXA-1 ST101 4
T3 Turkey 16 32 32 24 6 R T157P OXA-48 CTX-M-15 TEM-1, SHV-1, OXA-1 ST101 4
a ERT, ertapenem; IPM, imipenem; MEM, meropenem; DOR, doripenem; CST, colistin.
b R, resistant; S, susceptible.
c ESBL, extended-spectrum -lactamase.
d MLST, multilocus sequence type; ST, sequence type.
e PFGE, pulsed-ﬁeld gel electrophoresis.
f WT, wild type.
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the subsequentmodiﬁcation of the LPS did notmodify the growth
properties of resistant isolates (data not shown). This observation
was further conﬁrmed by the lack of difference between the
growth curves obtained for K. pneumoniae AF1b complemented
with wild-type PmrB protein (plasmid pTOPO-pmrB) (colistin-
susceptible) or not complemented with PmrB but with plasmid
pTOPO (pTOPO-mdh) (colistin-resistant) (data not shown).
Thr157Pro substitution in PmrB mutation associated with
overexpression of pmrCAB and pmrHFIJKLM operons. Expres-
sion levels of the pmr genes weremeasured in order to evaluate the
impact of the pmrB mutation. RT-PCR assays were performed
with isolates AF1a and AF1b, since they corresponded to likely
isogenic strains.Upregulation of the expression levels of the pmrC,
pmrA, pmrB, and pmrK genes was observed for AF1b compared to
that for the isogenic colistin-susceptible isolate AF1a. The relative
mean increases were estimated to be 170-fold for pmrC, 70-fold
for pmrA, 70-fold for pmrB, and 40-fold for pmrK, whereas no
signiﬁcant differences in expression levels were observed with the
pmrD and pmrE genes (increases of 1.9- and 1.4-fold, respectively)
(Fig. 1).
DISCUSSION
Since data on the molecular bases of colistin resistance in K. pneu-
moniae are scarce, we analyzed a collection of colistin-resistant
isolates of worldwide origin. Interestingly, we found six isolates
harboring an unique and identical amino acid substitution in the
protein PmrB. Complementation assays performed with a wild-
type PmrB protein generated a complete reversion of the colistin-
resistant trait. This result suggested that the PmrB substitution
identiﬁed (Thr157Pro) was involved in the resistance of the clin-
ical isolates. Of note, while this work was in progress, Choi and Ko
(18) identiﬁed the same mutation in a colistin-resistant K. pneu-
moniae isolate and suggested that it might be involved in colistin
resistance, but no further demonstration was provided to conﬁrm
this hypothesis. The involvement of the protein PmrB in resis-
tance to colistin correlates results obtained with colistin-resistant
Pseudomonas aeruginosa isolates (19) or colistin-resistantAcineto-
bacter baumannii isolates (20, 21).
Furthermore, since we had two very likely isogenic isolates
(one susceptible and one resistant) recovered from the same pa-
tient, this hypothesis was conﬁrmed by the identiﬁcation of this
same Thr to Pro substitution at position 157 in the colistin-resis-
tant isolate. Of note, the colistin-resistant isolate had been recov-
ered after a selective digestive tract decontamination process
based on oral colistin administration (17). Considering that a sin-
gle amino acid substitution in a single protein (here PmrB) may
generate resistance to colistin, we suggest that colistin-based oral
decontamination has to be used with caution.
The identiﬁcation of four clonally unrelatedK. pneumoniae clin-
ical isolates harboring the same Thr157Pro substitution in PmrB
is surprising considering that they have been recoveredworldwide
and do not correspond to the spread of a single clone. It strongly
suggests that position 157 in protein PmrB is a key position for
colistin resistance. It also suggests that the Pro residue might be a
key residue for resistance to colistin in K. pneumoniae, in contrast
to recent observations made in P. aeruginosa or A. baumannii
isolates from which many different amino acid substitutions oc-
curring in PmrB have been shown to be involved in colistin resis-
tance (18–20). Further studies, using site-directed mutagenesis in
PmrB, will be performed to evaluate our hypotheses, targeting
different positions, including amino acids at position 157.
Analysis of the pmrC, pmrA, and pmrB transcription levels by
qRT-PCR in isolate AF1b carrying a pmrB mutation compared to
those in the susceptible and isogenic AF1a indicated that this muta-
tion leads to an overexpression of the entire pmrCAB operon. This
result suggests that the modiﬁed PmrB induces the constitutive acti-
vation of PmrA, which in turn autoregulates (activates) the pmrCAB
promoter, as previously demonstrated in Salmonella spp. (6). Ex-
pression of the pmrC gene, being the ﬁrst gene in the pmrCAB
operon, has been shown to lead to phosphoethanolamine addi-
tion to lipid A in Salmonella spp. Moreover, analysis of the level of
transcription of the pmrK gene, which belongs to the pmrHFI-
JKLM operon, conﬁrmed that this operon was also activated by
PmrA as described previously (8). The products of this operon are
responsible for 4-deoxyaminoarabinose addition and therefore
modiﬁcation of the LPS target. Addition of both pEtN and Ara4N
to the LPS creates a more positively charged LPS molecule and
thus reduces the afﬁnity of positively charged polymyxins (6–8).
TABLE 3 MIC results for colistin and polymyxin B determined by broth microdilution before and after complementation with plasmids pTOPO-
mdh (negative control) and pTOPO-pmrB for the four clonally unrelated and colistin-resistant K. pneumoniae isolates
Isolate
MIC (g/ml) of colistin: MIC (g/ml) of polymyxin B:
Before
complementation
After complementation
with pTOPO-mdh
After complementation
with pTOPO-pmrB
Before
complementation
After complementation
with pTOPO-mdh
After complementation
with pTOPO-pmrB
AF1b 16 16 1 8 8 1
C3 16 16 2 8 8 1
C19 16 16 1 8 8 2
T2 16 16 1 8 8 2
FIG 1 Relative expression levels of the pmrC, pmrA, pmrB, pmrK, pmrE, and
pmrD genes in the AF1b colistin-resistant strain (ColR) compared with those
in the AF1a colistin-susceptible strain (ColS). Values are the means and the
standard deviations from three independent experiments.
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The expression of the pmrE genewas not signiﬁcantlymodiﬁed
here in the studied colistin-resistant K. pneumoniae isolates.
Therefore, in contrast to what has been observed for S. enterica
and E. coli (22), PmrA may upregulate pmrE expression in K.
pneumoniae. Also, the expression of the pmrD gene was not sig-
niﬁcantly modiﬁed, which is different from what has been ob-
served in S. enterica (23), for which the transcription of the pmrD
gene was repressed by the PmrA protein. Those ﬁndings are in
accordancewith data obtained byCheng et al. (3) showing that the
pmrD expression is independent of PmrA/PmrB in Klebsiella.
In conclusion, we showedhere that a speciﬁc pointmutation in
the PmrB protein is responsible for an upregulation of the pmr-
CAB and pmrHFIJKLM operons that confers resistance to colistin
in K. pneumoniae. The identiﬁcation of six clinical isolates of
worldwide origin belonging to four distinct clones with this same
substitution in PmrB suggests that this constitutes a clinically rel-
evant mechanism of resistance in K. pneumoniae. In addition, it
conﬁrms that the PmrAB two-component system plays a major
regulatory role in polymyxin B resistance in that species.
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